Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the sale, the chief executive officer owned 1,613,063 shares in the company, valued at $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Eric Venker also recently made the following trade(s):

• On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00.
• On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $28.24, for a total transaction of $5,648,000.00.

Roivant Sciences Trading Down 3.0%

NASDAQ:ROIV traded down $0.92 during midday trading on Friday, hitting $29.96. 5,873,872 shares of the company were exchanged, compared to its average volume of 6,125,914. The company has a fifty day simple moving average of $28.46 and a 200 day simple moving average of $25.02. Roivant Sciences Ltd. has a fifty-two week low of $10.59 and a fifty-two week high of $32.79. The company has a market capitalization of $21.44 billion, a PE ratio of -49.93 and a beta of 1.14.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same period last year, the business earned ($0.29) EPS. As a group, equities research analysts expect that Roivant Sciences Ltd. will post -1.06 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Fifth Third Bancorp increased its stake in shares of Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after acquiring an additional 376 shares during the period. Bessemer Group Inc. increased its stake in shares of Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares during the period. Fifth Third Wealth Advisors LLC increased its stake in shares of Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after acquiring an additional 445 shares during the period. Oregon Public Employees Retirement Fund increased its stake in shares of Roivant Sciences by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after acquiring an additional 500 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Roivant Sciences by 1.3% during the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after acquiring an additional 516 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on ROIV. Weiss Ratings restated a “sell (d)” rating on shares of Roivant Sciences in a research note on Friday, May 8th. Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. TD Cowen lifted their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday. Finally, Citigroup lifted their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $33.05.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.